The NordCAN study: Cannabis treatment in hand osteoarthritis and psoriatic arthritis. A randomized, double-blind placebo controlled study - NordCA

Aalborg university hospital dept. of rheumatology0 个研究点目标入组 160 人开始时间: 2018年3月8日最近更新: 2021年7月5日

试验速览

暂无简介。

•Patients (18 years or older) with Hand-OA according to the American collage of rheumatology (ACR) criteria (1990)
•Hand-OA of the phenotype: Nodal, Non-erosive.
•Ability and willingness to give written informed consent and to meet the requirements of the study protocol.
•100mm VAS pain during the last 24 hours over or equal to 30mm
•Patients (18 years or older) with PsA according to the classification criteria for psoriatic arthritis CASPAR criteria (2006)
•Ability and willingness to give written informed consent and to meet the requirements of the study protocol.
•100mm VAS pain during the last 24 hours over or equal to 30mm
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 120
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 40

•Hand-Oa and PsA
•1.Other known inflammatory rheumatic disease (i.e. Rheumatoid arthritis, gout)
•2.Other known pain condition (i.e. fibromyalgia, Carpel tunnel syndrome, polyneuropathy)
•3.Addictive behaviour or previously addictive behaviour defined as abuse of cannabis, opioids or other recreational or pharmaceutical drugs
•4.History of psychiatric disease that contraindicates use of medical cannabis treatment (i.e. schizophrenia).

发起方

Aalborg university hospital dept. of rheumatology